Michel Dard of BioCellgraft Wins Business Worldwide Magazines 2025 CEO Award [Yahoo! Finance]
Celularity Inc. - Class A (CELU)
Company Research
Source: Yahoo! Finance
New York, the 'Biotech CEO of the Year U.S. – Regenerative Dentistry and Oral Medicine' title in the 2025 CEO Awards. Michel Dard, DDS, MS, PhD, CEO of BioCellgraft, Inc. (Source: Business Worldwide Magazine) The 2025 CEO Awards honours senior executives whose vision, strategy, and leadership drive innovation and inspire the broader business community. Unlike other business awards, which focus on the overall achievements of companies, here the spotlight is on the visionaries who lead them. The aim is to give groundbreaking business leaders the recognition they deserve, whilst inspiring others to achieve similar successes. A trained dentist in France and oral surgeon in the United States, Dard has held senior roles across academia, hospitals, and global corporations. Today, he applies decades of experience to BioCellgraft's pioneering regenerative solutions, developing minimally invasive treatments that address both soft and hard tissue defects. "I was always curious to explore
Show less
Read more
Impact Snapshot
Event Time:
CELU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELU alerts
High impacting Celularity Inc. - Class A news events
Weekly update
A roundup of the hottest topics
CELU
News
- Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye CareGlobeNewswire
- Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery DiseaseGlobeNewswire
- Celularity (NASDAQ:CELU) was upgraded by analysts at WBB Securities from a "hold" rating to a "buy" rating. They now have a $6.00 price target on the stock.MarketBeat
CELU
Sec Filings
- 11/21/25 - Form 4
- 11/21/25 - Form 4
- 11/21/25 - Form 4
- CELU's page on the SEC website